메뉴 건너뛰기




Volumn 109, Issue 51, 2012, Pages 21046-21051

Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel

Author keywords

Anti ERBB1 therapy; High throughput screening; Immune mediated killing

Indexed keywords

AMPHIREGULIN; B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; LAPATINIB; MESSENGER RNA; PERTUZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

EID: 84871368013     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1218750110     Document Type: Article
Times cited : (45)

References (33)
  • 1
    • 54949110541 scopus 로고    scopus 로고
    • Targeting EGFR in colorectal cancer
    • Messersmith WA, Ahnen DJ (2008) Targeting EGFR in colorectal cancer. N Engl J Med 359(17):1834-1836.
    • (2008) N Engl J Med , vol.359 , Issue.17 , pp. 1834-1836
    • Messersmith, W.A.1    Ahnen, D.J.2
  • 2
    • 79956298812 scopus 로고    scopus 로고
    • Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status
    • Van Cutsem E, et al. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15):2011-2019.
    • (2011) J Clin Oncol , vol.29 , Issue.15 , pp. 2011-2019
    • Van Cutsem, E.1
  • 3
    • 79957523828 scopus 로고    scopus 로고
    • KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer
    • De Roock W, et al. (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12(6):594-603.
    • (2011) Lancet Oncol , vol.12 , Issue.6 , pp. 594-603
    • De Roock, W.1
  • 4
    • 67649506174 scopus 로고    scopus 로고
    • Genetic prognostic and predictive markers in colorectal cancer
    • Walther A, et al. (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9(7):489-499.
    • (2009) Nat Rev Cancer , vol.9 , Issue.7 , pp. 489-499
    • Walther, A.1
  • 5
    • 33646352962 scopus 로고    scopus 로고
    • Potent antibody therapeutics by design
    • Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6(5): 343-357.
    • (2006) Nat Rev Immunol , vol.6 , Issue.5 , pp. 343-357
    • Carter, P.J.1
  • 6
    • 61449239114 scopus 로고    scopus 로고
    • Impact of FcgammaRIIa-FcgammaRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan
    • Bibeau F, et al. (2009) Impact of FcgammaRIIa-FcgammaRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27(7):1122-1129.
    • (2009) J Clin Oncol , vol.27 , Issue.7 , pp. 1122-1129
    • Bibeau, F.1
  • 7
    • 62449302407 scopus 로고    scopus 로고
    • PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
    • Sartore-Bianchi A, et al. (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69(5):1851-1857.
    • (2009) Cancer Res , vol.69 , Issue.5 , pp. 1851-1857
    • Sartore-Bianchi, A.1
  • 8
    • 74249093155 scopus 로고    scopus 로고
    • PTEN status in advanced colorectal cancer treated with cetuximab
    • Negri FV, et al. (2010) PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 102(1):162-164.
    • (2010) Br J Cancer , vol.102 , Issue.1 , pp. 162-164
    • Negri, F.V.1
  • 9
    • 77955277111 scopus 로고    scopus 로고
    • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
    • De Roock W, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy- refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11(8):753-762.
    • (2010) Lancet Oncol , vol.11 , Issue.8 , pp. 753-762
    • De Roock, W.1
  • 10
    • 80054718129 scopus 로고    scopus 로고
    • A phase II trial of lapatinib and capecitabine for patients with refractory advanced colorectal adenocarcinoma
    • abstr
    • Frank D, et al. (2010) A phase II trial of lapatinib and capecitabine for patients with refractory advanced colorectal adenocarcinoma. J Clin Oncol 28(suppl; abstr):e14092.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL.
    • Frank, D.1
  • 11
    • 53249123419 scopus 로고    scopus 로고
    • Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: A fluorescent in situ hybridization study
    • Personeni N, et al. (2008) Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: A fluorescent in situ hybridization study. Clin Cancer Res 14(18):5869-5876.
    • (2008) Clin Cancer Res , vol.14 , Issue.18 , pp. 5869-5876
    • Personeni, N.1
  • 12
    • 77950673501 scopus 로고    scopus 로고
    • Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer
    • Hecht JR, et al. (2010) Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 16(7):2205-2213.
    • (2010) Clin Cancer Res , vol.16 , Issue.7 , pp. 2205-2213
    • Hecht, J.R.1
  • 13
    • 73349098041 scopus 로고    scopus 로고
    • Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab
    • Jacobs B, et al. (2009) Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27(30):5068-5074.
    • (2009) J Clin Oncol , vol.27 , Issue.30 , pp. 5068-5074
    • Jacobs, B.1
  • 14
    • 70449427821 scopus 로고    scopus 로고
    • Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis
    • Ashraf SQ, et al. (2009) Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis. Br J Cancer 101(10):1758-1768.
    • (2009) Br J Cancer , vol.101 , Issue.10 , pp. 1758-1768
    • Ashraf, S.Q.1
  • 15
    • 33645218704 scopus 로고    scopus 로고
    • Engineered antibody Fc variants with enhanced effector function
    • Lazar GA, et al. (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103(11):4005-4010.
    • (2006) Proc Natl Acad Sci USA , vol.103 , Issue.11 , pp. 4005-4010
    • Lazar, G.A.1
  • 16
    • 77955058495 scopus 로고    scopus 로고
    • 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency
    • Bracht K, et al. (2010) 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency. Br J Cancer 103(3):340-346.
    • (2010) Br J Cancer , vol.103 , Issue.3 , pp. 340-346
    • Bracht, K.1
  • 17
    • 77949957365 scopus 로고    scopus 로고
    • Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
    • Sharma SV, et al. (2010) Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 10(4):241-253.
    • (2010) Nat Rev Cancer , vol.10 , Issue.4 , pp. 241-253
    • Sharma, S.V.1
  • 18
    • 84859187259 scopus 로고    scopus 로고
    • Systematic identi fication of genomic markers of drug sensitivity in cancer cells
    • Garnett MJ, et al. (2012) Systematic identi fication of genomic markers of drug sensitivity in cancer cells. Nature 483(7391):570-575.
    • (2012) Nature , vol.483 , Issue.7391 , pp. 570-575
    • Garnett, M.J.1
  • 19
    • 84859169877 scopus 로고    scopus 로고
    • The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
    • Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603-607.
    • (2012) Nature , vol.483 , Issue.7391 , pp. 603-607
    • Barretina, J.1
  • 20
    • 40949135397 scopus 로고    scopus 로고
    • PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
    • Jhawer M, et al. (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68(6):1953-1961.
    • (2008) Cancer Res , vol.68 , Issue.6 , pp. 1953-1961
    • Jhawer, M.1
  • 21
    • 33747886889 scopus 로고    scopus 로고
    • Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib
    • Cunningham MP, et al. (2006) Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cancer Res 66(15):7708-7715.
    • (2006) Cancer Res , vol.66 , Issue.15 , pp. 7708-7715
    • Cunningham, M.P.1
  • 22
    • 65649086786 scopus 로고    scopus 로고
    • PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer
    • Prenen H, et al. (2009) PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 15(9):3184-3188.
    • (2009) Clin Cancer Res , vol.15 , Issue.9 , pp. 3184-3188
    • Prenen, H.1
  • 23
    • 57449095367 scopus 로고    scopus 로고
    • Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
    • Di Nicolantonio F, et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26(35):5705-5712.
    • (2008) J Clin Oncol , vol.26 , Issue.35 , pp. 5705-5712
    • Di Nicolantonio, F.1
  • 24
    • 84863230465 scopus 로고    scopus 로고
    • Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
    • Prahallad A, et al. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483(7387):100-103.
    • (2012) Nature , vol.483 , Issue.7387 , pp. 100-103
    • Prahallad, A.1
  • 25
    • 79551580548 scopus 로고    scopus 로고
    • Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
    • Baker JB, et al. (2011) Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 104(3):488-495.
    • (2011) Br J Cancer , vol.104 , Issue.3 , pp. 488-495
    • Baker, J.B.1
  • 26
    • 53249137803 scopus 로고    scopus 로고
    • Molecular association between beta-catenin degradation complex and Rac guanine exchange factor DOCK4 is essential for Wnt/beta-catenin signaling
    • Upadhyay G, et al. (2008) Molecular association between beta-catenin degradation complex and Rac guanine exchange factor DOCK4 is essential for Wnt/beta-catenin signaling. Oncogene 27(44):5845-5855.
    • (2008) Oncogene , vol.27 , Issue.44 , pp. 5845-5855
    • Upadhyay, G.1
  • 27
    • 17844362179 scopus 로고    scopus 로고
    • Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study
    • Moroni M, et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6(5):279-286.
    • (2005) Lancet Oncol , vol.6 , Issue.5 , pp. 279-286
    • Moroni, M.1
  • 28
    • 20144381957 scopus 로고    scopus 로고
    • Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
    • Chung KY, et al. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23(9):1803-1810.
    • (2005) J Clin Oncol , vol.23 , Issue.9 , pp. 1803-1810
    • Chung, K.Y.1
  • 29
    • 46249087766 scopus 로고    scopus 로고
    • Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members
    • Wheeler DL, et al. (2008) Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members. Oncogene 27(28):3944-3956.
    • (2008) Oncogene , vol.27 , Issue.28 , pp. 3944-3956
    • Wheeler, D.L.1
  • 30
    • 0022446735 scopus 로고
    • Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms
    • Epenetos AA, Snook D, Durbin H, Johnson PM, Taylor-Papadimitriou J (1986) Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res 46(6):3183-3191.
    • (1986) Cancer Res , vol.46 , Issue.6 , pp. 3183-3191
    • Epenetos, A.A.1    Snook, D.2    Durbin, H.3    Johnson, P.M.4    Taylor-Papadimitriou, J.5
  • 31
    • 0035256698 scopus 로고    scopus 로고
    • Untangling the ErbB signalling network
    • Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127-137.
    • (2001) Nat Rev Mol Cell Biol , vol.2 , Issue.2 , pp. 127-137
    • Yarden, Y.1    Sliwkowski, M.X.2
  • 32
    • 0033044588 scopus 로고    scopus 로고
    • Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity
    • Umaña P, et al. (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17(2):176-180.
    • (1999) Nat Biotechnol , vol.17 , Issue.2 , pp. 176-180
    • Umaña, P.1
  • 33
    • 80053644648 scopus 로고    scopus 로고
    • Phase i pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors
    • Paz-Ares LG, et al. (2011) Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 29(28):3783-3790.
    • (2011) J Clin Oncol , vol.29 , Issue.28 , pp. 3783-3790
    • Paz-Ares, L.G.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.